• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

    14.94 +0.59 (+4.11%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,035,886
    Open 14.40
    Bid (Size) 14.45 (200)
    Ask (Size) 14.94 (400)
    Prev. Close 14.35
    Today's Range 14.08 - 15.13
    52wk Range 5.970 - 16.93
    Shares Outstanding 42,052,980
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +104.1%
    +104.1%
    1 Month
    +48.1%
    +48.1%
    3 Month
    +61.2%
    +61.2%
    6 Month
    +76.6%
    +76.6%
    1 Year
    +143.3%
    +143.3%

    More News

    Read More
    News headline image
    4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4D Molecular Therapeutics (NASDAQ:FDMT) Q1 2026: Revenue Miss and Wider Losses Overshadow Phase 3 Progress ↗
    Via Chartmill
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy ↗
    Via MarketBeat
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Upcoming Investor Meetings
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Provides Company Update and Anticipated Development Milestones for 2026
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT Announces New Employment Inducement Grants
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is 4D Molecular Therapeutics, Inc. - Common Stock publicly traded?
    Yes, 4D Molecular Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does 4D Molecular Therapeutics, Inc. - Common Stock trade on?
    4D Molecular Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock?
    The ticker symbol for 4D Molecular Therapeutics, Inc. - Common Stock is FDMT on the Nasdaq Stock Market
    What is the current price of 4D Molecular Therapeutics, Inc. - Common Stock?
    The current price of 4D Molecular Therapeutics, Inc. - Common Stock is 14.94
    When was 4D Molecular Therapeutics, Inc. - Common Stock last traded?
    The last trade of 4D Molecular Therapeutics, Inc. - Common Stock was at 09/02/26 04:00 PM ET
    What is the market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock?
    The market capitalization of 4D Molecular Therapeutics, Inc. - Common Stock is 628.27M
    How many shares of 4D Molecular Therapeutics, Inc. - Common Stock are outstanding?
    4D Molecular Therapeutics, Inc. - Common Stock has 628M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.